Studies undertaken at The Pirbright Institute in collaboration with Inovio Pharmaceuticals have shown that pigs can be used to assess whether influenza antibody therapies are effective, which could provide a better indication of their success in humans than small animal trials. They also demonstrated pigs are suitable for analysing the delivery systems used to administer the antibodies in order to provide longer lasting protection.
Work carried out by scientists at The Pirbright Institute has revealed that differences in virulence between strains of infectious bursal disease virus (IBDV) may be partly down to changes in a viral protein called VP4. Their findings could help us to understand why very virulent (vv) strains cause high mortality rates in some commercial poultry flocks and could also be used to inform vaccine research and surveillance efforts.
Studies at Pirbright demonstrate two doses of Oxford University’s COVID-19 vaccine boosts immune response in pigs
The Pirbright Institute, working in collaboration with the University of Oxford, have successfully shown that two doses of the ChAdOx1 nCoV-19 (AZD1222) vaccine produce a greater antibody response than a single dose in pigs.
The emergence and subsequent spread of SARS-CoV-2 has caused a global pandemic that continues to have a huge impact on human health and welfare, and the world economy. Vaccines to protect against COVID-19 and to reduce SARS-CoV-2 transmission are urgently required to combat this global emergency.